Section Arrow
CHRS.NASDAQ
- Coherus Oncology Inc
Quotes are at least 15-min delayed:2026/04/07 14:55 EDT
Regular Hours
Last
 1.645
-0.025 (-1.50%)
Day High 
1.7099 
Prev. Close
1.67 
1-M High
2.0598 
Volume 
552.42K 
Bid
1.64
Ask
1.65
Day Low
1.59 
Open
1.67 
1-M Low
1.52 
Market Cap 
249.62M 
Currency 美元 
P/E 3.16 
%Yield -- 
10-SMA 1.68 
20-SMA 1.69 
50-SMA 1.83 
52-W High 2.6158 
52-W Low 0.71 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.43/-0.87
Enterprise Value
288.12M
Balance Sheet
Book Value Per Share
0.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
42.17M
Operating Revenue Per Share
1.41
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QNCXQuince Therapeutics0.1541+0.0666+76.11%-- 
LNAILunai Bioworks Inc.0.3959+0.1139+40.39%-- 
SILOSilo Pharma0.5125+0.1567+44.04%-- 
TERNTerns Pharmaceuticals52.615-0.165-0.31%-- 
CUECue Biopharma0.1841+0.0071+4.01%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.